Elutia (Nasdaq:ELUT) - Stock Price, News & Analysis

ELUT Stock Overview

Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes.

ELUT fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at good value compared to peers and industry

Risk Analysis

Highly volatile share price over the past 3 months

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk

Elutia Inc. Competitors

Kineta

NasdaqCM:KA

US$21.6m

Impel Pharmaceuticals

NasdaqGM:IMPL

US$12.8m

Aprea Therapeutics

NasdaqCM:APRE

US$16.3m

Azitra

NYSEAM:AZTR

US$21.5m

Price History & Performance

Summary of all time highs, changes and price drops for Elutia
Historical stock prices
Current Share Price	US$1.53
52 Week High	US$9.01
52 Week Low	US$1.10
Beta	-0.085
1 Month Change	0%
3 Month Change	-40.70%
1 Year Change	-77.43%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-89.45%

Recent updates

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Apr 17

Are Institutions Heavily Invested In Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Shares?

Jan 11

Aziyo Biologics EPS of -$15.79

Nov 19

Shareholder Returns

	ELUT	US Biotechs	US Market
7D	33.0%	-0.5%	-1.5%
1Y	-77.4%	10.8%	13.8%

Return vs Industry: ELUT underperformed the US Biotechs industry which returned 10.8% over the past year.

Return vs Market: ELUT underperformed the US Market which returned 13.8% over the past year.

Price Volatility

Is ELUT's price volatile compared to industry and market?
ELUT volatility
ELUT Average Weekly Movement	14.5%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.6%
10% most volatile stocks in US Market	14.3%
10% least volatile stocks in US Market	2.5%

Stable Share Price: ELUT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ELUT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2015	151	Randy Mills	https://www.elutia.com

Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. It offers CanGaroo Envelope, which is used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. The company also engages in the development of CanGaroo RM for delivery directly to the surgical site.

Elutia Inc. Fundamentals Summary

How do Elutia's earnings and revenue compare to its market cap?
ELUT fundamental statistics
Market Cap	US$26.16m
Earnings (TTM)	-US$33.94m
Revenue (TTM)	US$48.40m

0.5x

P/S Ratio

-0.7x

P/E Ratio

Is ELUT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ELUT income statement (TTM)
Revenue	US$48.40m
Cost of Revenue	US$31.05m
Gross Profit	US$17.35m
Other Expenses	US$51.30m
Earnings	-US$33.94m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.09
Gross Margin	35.86%
Net Profit Margin	-70.13%
Debt/Equity Ratio	-112.6%

How did ELUT perform over the long term?

See historical performance and comparison

ELUT Stock Overview

Rewards

Risk Analysis

Elutia Inc. Competitors

NasdaqCM:KA

US$21.6m

NasdaqGM:IMPL

US$12.8m

NasdaqCM:APRE

US$16.3m

NYSEAM:AZTR

US$21.5m

Price History & Performance

Recent News & Updates

Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT) for $35 million.

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates decrease by 25%, EPS upgraded

Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products

Recent updates

Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT) for $35 million.

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates decrease by 25%, EPS upgraded

Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products

Price target decreased by 17% to US$10.00

Aziyo Biologics, Inc. Presents Positive Clinical Data on Cangaroo® Biologic Envelope

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.60 loss in 1Q 2022)

Aziyo Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Full year 2022 earnings released

Aziyo Biologics, Inc. Provides Preliminary Sales Guidance for the Fourth Quarter and Full Year 2022

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Aziyo Biologics appoints Williams as Chief Scientific Officer

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Announces Randal Mills as Chief Executive Officer

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aziyo Biologics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Aziyo Biologics, Inc. Appoints C. Randal (Randy) Mills, Ph.D. as Interim President

Aziyo Biologics Receives a Written Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Confirms Financial Guidance for Year 2022

Price target decreased to US$13.00

Aziyo Biologics, Inc. to Report Q1, 2022 Results on May 09, 2022

Aziyo Biologics, Inc., Annual General Meeting, Jun 07, 2022

Aziyo Biologics, Inc. Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

Consensus EPS estimates fall by 10%

Aziyo Biologics, Inc. Provides Net Sales Guidance for the Full Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Aziyo Biologics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Aziyo Biologics, Inc. announced that it has received $13.999976 million in funding

Aziyo Biologics, Inc. announced that it expects to receive $13.999976 million in funding

Aziyo Biologics Receives Notice from Nasdaq Stating Non Compliance with Nasdaq Listing Rule 5450(B)(1)(A)

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$15.79 loss in 3Q 2020)

Price target decreased to US$15.00

Price target decreased to US$15.75

Price target decreased to US$15.75

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$7.99 loss in 2Q 2020)

Aziyo Biologics, Inc.(NasdaqGM:AZYO) dropped from Russell Microcap Value Index

A Retired Career Corrections Officer Lawsuit Files Against Aziyo Biologics, Inc. and Medtronic, Inc. on Behalf of Delaware Patient Infected with Tuberculosis After Receiving Tainted Surgical Bone Graft Product During Spinal Fusion

Aziyo Biologics Announces Voluntary Recall of One Lot of its FiberCel Fiber Viable Bone Matrix

CEO, President & Director recently bought US$101k worth of stock

First quarter 2021 earnings released: US$0.49 loss per share (vs US$7.03 loss in 1Q 2020)

Aziyo Biologics, Inc. Updates Revenue Guidance for the Full Year 2021

Aziyo Biologics initiates de novo CanGaroo Envelope study

Full year 2020 earnings released: US$8.88 loss per share (vs US$1.32 loss in FY 2019)

Revenue beats expectations

Aziyo Biologics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Aziyo Biologics Announces Product Design Completion for Its Next Generation CanGaroo® Envelope for Implantable Electronic Devices

New 90-day high: US$16.18

New 90-day high: US$15.62